In its second-quarter results, Novo disclosed a partial miss in a Phase 3 diabetes trial of CagriSema. And it ended work on an asset that it got when it bought Inversago Pharma.
Novo Nordisk is under pressure, but CEO Mike Doustdar got philosophical about it.
“If you don’t like setbacks and you don’t like failure, don’t get …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline
Novo Nordisk shares slide after guidance disappoints investors
Lilly climbs, Novo falls as obesity drug battle intensifies
Novo Dives On A Key Miss As Its Battle With Lilly Heats Up
Novo Nordisk inflammation-targeting drug misses mark in heart disease study
Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug…
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its…
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of…
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S.…
The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways
An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between…
